about
Understanding cognition in older patients with cancerChemotherapy-related cognitive impairment in older patients with cancerChemotherapy of ovarian cancer in elderly patientsSystemic therapy of non-colorectal gastrointestinal malignancies in the elderlyESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryDistress in older patients with cancerPolypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment.The relationship between age, anxiety, and depression in older adults with cancer.The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.Predictors of chemotherapy dose reduction at first cycle in patients age 65 years and older with solid tumors.Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907.Care of elderly women with ovarian cancer.Use of complementary medications among older adults with cancer.Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG).Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly.Treatment of elderly cancer patients with chemotherapy.Therapy insight: Therapeutic challenges in the treatment of elderly cancer patients.Doublet chemotherapy in the elderly patient with ovarian cancer.Clinical pharmacology of cancer therapies in older adults.Management of colorectal cancer in older patients.International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency.Pharmacokinetics of chemotherapy in the older patient.Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.Anemia and Functional Disability in Older Adults With Cancer.Toxicity of bevacizumab in combination with chemotherapy in older patientsInternational Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature.Long-term Toxicity of Cancer Treatment in Older PatientsA novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes.CA125 level association with chemotherapy toxicity and functional status in older women with ovarian cancer.Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older PatientsAnticancer drug therapy in the older cancer patient: pharmacology and polypharmacy.Effect of age on drug metabolism in women with breast cancer.Ovarian cancer in older women.Chemotherapy options and outcomes in older adult patients with colorectal cancer.Chemotherapy for the elderly patient with colorectal cancer.Pharmacology of aging and cancer: how useful are pharmacokinetic tests?.Global initiatives to enhance cancer care in areas of limited resources: what ASCO members are doing and how you can become involved.How I treat ovarian cancer in older women.Prescribing for older patients with cancer.
P50
Q26747296-0182F2E5-0A6F-4548-91BF-3A46AD22C3ADQ26747612-0B911FD8-B1E2-48EA-80B4-9112AD93D020Q26771397-1A2DEFF7-3B77-4A09-BE75-DEDCA11A595BQ26771399-6692CA09-C69F-43A0-8839-0B34C88B92A7Q27928062-1D8DAA46-973E-4BD6-91D0-AC04EC2C710EQ28088365-88AAB68A-134A-4E59-9C79-64587ECB2223Q33561136-00D21263-6FD2-4C3B-8CB3-5842EB5A8C85Q34051261-099840A1-0075-482C-BF10-324622B79077Q35058648-D7A2F60F-D849-4917-8D98-23AF55EEF6FEQ35205223-1FB4A384-7B32-4713-B75F-A4E0B7149687Q35771257-C35B3753-0CBB-462A-A2CD-CA28BB7164F1Q35891359-EC6096A6-5CFB-4199-BAD3-D101EB05E5B5Q35980865-4AD1676A-F5A4-4CC4-AEAD-65AFFAF7EB2CQ36004580-942D6D6A-0307-42FD-9B4A-FC5C13328BF4Q36220834-2A22F232-9A8B-4904-A9BA-281D48B51D23Q36263996-6DC241A8-8FD3-4489-8A5E-825A91939023Q36276360-16C5B02E-5B6D-486E-9DE1-007E73A079A4Q36389319-1BD7366B-BF8C-4B45-8384-3C328F5B2349Q36405668-5E3B8445-B346-44FB-82FF-C9D9E592D4E3Q36459787-4FF1E34E-0FFD-4D8A-B800-797677A017FDQ36536024-4A2AF0F6-1570-49CC-8F9F-DC28F4A8867EQ36707821-FAEF8E7C-EECB-4E39-91C1-979A42081860Q36715263-F9AD9AA1-146F-4118-B64F-E056BBB0F074Q36760924-1EA8C15C-D62C-4004-ABB8-C50B56EDA291Q36800253-690696A5-3C7A-4322-86B9-F0B7A2253483Q36804502-D6418F4D-2275-4629-B188-C4B418459A02Q36815528-E97DD081-BCC8-4EF5-9119-259DB165DFAFQ36821673-BED49E57-BC89-4CBA-96A3-A63CDE03FBBDQ36936263-6182EFCE-66D2-454D-B653-85C601240A31Q37169517-41073828-8F71-4C1F-808B-691451B56676Q37191051-B605BA28-582C-478D-9CA7-55491F8AA470Q37229270-16C3B664-3B1C-4E11-8CA8-9673D01DC078Q37325560-6D92C6D0-A430-41A0-BD67-482E0143FE96Q37332608-3AC5C888-0F91-4E4F-9DDB-CF4B64EA4ADBQ37438959-8D8CC60B-9132-4A30-9A6E-9BFB69D13111Q37762946-AFE31390-7627-4067-B01A-A823598F2B28Q38090448-2EACA715-0968-489D-BAA9-8EDF69C5B769Q38110090-8D275D05-31DA-47A0-86D9-5E8A96F4F2C7Q38222420-97B8AF5B-8B20-42BD-AD53-BC62311DA02DQ38227238-9F921C8A-455A-493C-8381-E7E2616D278A
P50
description
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Stuart M Lichtman
@ast
Stuart M Lichtman
@en
Stuart M Lichtman
@es
Stuart M Lichtman
@nl
type
label
Stuart M Lichtman
@ast
Stuart M Lichtman
@en
Stuart M Lichtman
@es
Stuart M Lichtman
@nl
prefLabel
Stuart M Lichtman
@ast
Stuart M Lichtman
@en
Stuart M Lichtman
@es
Stuart M Lichtman
@nl
P214
P244
P106
P21
P214
P244
n2005184211
P31
P496
0000-0003-4146-6192
P734
P735
P7859
lccn-n2005184211